Lys221

Site Information
sCGPIkVkTEPTEDS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 40724403

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 4 ) , mutation of modification site ( 1 )
Disease tissue studied:	liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:	293N3S (epithelial) ( 4 ) , HCCLM3 (hepatic) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) [SUMO2 (human), transfection, SUMO2 K0 Q87R (lysine-deficient SUMO2, with Q87R to create convenient Trypsin cleavage site)] ( 2 ) , Hep3B (hepatic) ( 1 ) , HepG2 (hepatic) ( 1 ) , Huh7 (hepatic) ( 1 )

Downstream Regulation
Effects of modification on GTF2I:	molecular association, regulation ( 1 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )
Inhibit interaction with:	HDAC3 (human) ( 1 )

References
1	Tu J, et al. (2015) Functional Proteomics Study Reveals SUMOylation of TFII-I is Involved in Liver Cancer Cell Proliferation. J Proteome Res 14, 2385-97 25869096 Curated Info
2	Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36 25218447 Curated Info
3	Impens F, Radoshevich L, Cossart P, Ribet D (2014) Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc Natl Acad Sci U S A 111, 12432-7 25114211 Curated Info
4	Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7, rs2 24782567 Curated Info